Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro

Breast Cancer Research and Treatment

Volumn 55, Issue 1, 1999, Pages 9-20

  Sieuwerts, Anieta M ^a,b   Klijn, Jan G M ^a   Henzen Logmans, Sonja C ^a   Foekens, John A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Cytokines; Growth factors; Human breast (myo)fibroblasts; In vitro; Urokinase plasminogen activator

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ALPHA ACTIN; BASIC FIBROBLAST GROWTH FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MESSENGER RNA; ONCOSTATIN M; PLATELET DERIVED GROWTH FACTOR BB; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ARTICLE; BREAST CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MYOFIBROBLAST; PHENOTYPE; PRIORITY JOURNAL;

BREAST; BREAST NEOPLASMS; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; TRANSFORMING GROWTH FACTOR BETA; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032866806     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006190729866     Document Type: Article

References (44)

1. 1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980
2. 2. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen PI, Nielsen BS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985
3. 3. Andreasen PA, Kjøller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72:1-22, 1997
4. 4. Clarke R, Dickson RB, Lippman ME: Hormonal aspects of breast cancer, growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 12: 1-23, 1992
5. 5. Martinez-Hernandez A: The extracellular matrix and neoplasia. Lab Invest 58: 609-612, 1988
6. 6. Barsky SH, Gopalakrishna R: Increased invasion and spontaneous metastasis of BL6 melanoma with inhibition of the desmoplastic response in C57 BL/6 mice. Cancer Res 47: 1663-1667, 1987
7. 7. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (London) 348: 699-704, 1990
8. 8. Wolf C, Rouer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Nat Acad Sci (Washington) 90: 1843-1847, 1993
9. 9. Uría JA, Stahle-Bäckdhal M, Seiki M, Fueyo A, López-Otín C: Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 57: 4882-4888, 1997
10. 10. Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K: Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74: 168-177, 1996
11. 11. Campbell PG, Novak JF, Yanosick TB, McMaster JH: Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130: 1401-1412, 1992
12. 12. Brunner G, Gabrilove J, Rifkin DB, Wilson EL: Phospholipase C release of basic fibroblast growth factor human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 114: 1275-1283, 1991
13. 13. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB: Latent transforming growth factor-beta: Structural features and mechanisms of activation. Kidney Int 51: 1376-1382, 1997
14. 14. Van Roozendaal CEP, Klijn JGM, Sieuwerts AM, Henzen-Logmans SC, Foekens JA: Role of urokinase plasminogen activator in human breast cancer: Active involvement of stromal fibroblasts. Fibrinolysis 10: 79-83, 1996
15. 15. Sappino A-P, Skalli O, Jackson W, Schürch W, Gabbiani G: Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer 41: 707-712, 1988
16. 16. Van Roozendaal CEP, Klijn JGM, Van Ooien B, Claassen C, Eggermont AMM, Henzen-Logmans SC, Foekens JA: Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinal 111: 1-6, 1995
17. 1) compared with factor(s) released by human epithelial-carcinoma cells. Int J Cancer 76: 829-835, 1998
18. 18. Grebensehikov N, Geurts-Moespot A, De Witte M, Heuvel J, Leake R, Sweep F, Benraad T: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-I) in breast tumor cytosols. Int J Biol Markers 12: 6-14, 1997
19. 1 in quiescent human breast gland fibroblasts. Lab Invest 68: 696-707, 1993
20. 20. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report. Cancer 62: 531-533, 1988
21. 21. Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992
22. 22. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H: Clinical impact of the plasminogen activator system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thromb Hemost 78: 285-296, 1997
23. 23. Foekens JA, Look MP, Peters HA, Van Putten WLJ, Portengen M, Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995
24. 24. Reiss M, Barcellos-Hoff H: Transforming growth factor-β in breast cancer: a working hypothesis. Breast Cancer Res Treat 45: 81-95, 1997
25. 25. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME: Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51: 4978-4985, 1991
26. 26. Van Roozendaal CEP, Klijn JGM, Van Ooijen B, Claassen C, Eggermont AMM, Henzen-Logmans SC, Foekens JA: Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol 111: 1-6, 1995
27. 27. Ghahary A, Shen Q, Shen YJ, Scott PG, Tredget EE: Induction of transforming growth factor beta-1 by insulin-like growth factor-1 in dermal fibroblasts. J Cell Physiol 174: 103-107, 1998
28. 28. Seppa H, Grotendorst G, Seppa S, Schiffermann E, Martin GR: Platelet-derived growth factor is chemotactic for fibroblasts. J Cell Biol 92: 584-588, 1982
29. 29. Seymour L, Bezwoda WR: Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 32: 229-233, 1994
30. 30. Blasi F: uPA, uPAR, PAI-I: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18: 415-417, 1997
31. 31. Cullen B, Silcock D, Brown J, Gosiewska A, Geesin JC: The differential regulation and secretion of proteinases from fetal and neonatal fibroblasts by growth factors. Int J Biochem Cell Biol 29: 241-250, 1997
32. 32. Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22: 31-38, 1992
33. 33. Besser D, Presta M, Nagamine Y: Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Diff 6: 1009-1017, 1995
34. 34. Visscher DW, Demattia F, Ottosen S, Sarjer FH, Crissman JD: Biological and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Modern Path 8: 665-670, 1995
35. 35. Cordon-Cardo C, Vlodavsky I, Haimovitz-Friedman A, Hicklin D, Fuks Z: Expression of basic fibroblast growth factor in normal tissue. Lab Invest 63: 832-840, 1990
36. 36. Anandappa SY, Winstanley JHR, Leinster S, Green B, Rudland PS, Barraclough R: Comparative expression of fibroblast growth factor mRNA in benign and malignant breast disease. Br J Cancer 69: 772-776, 1994
37. 37. Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, Coombes RC, Johnston CL: Fibroblast growth factor 2 in breast cancer: Occurence and prognostic significance. Br J Cancer 75: 28-33, 1997
38. 38. McLesky SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat 39: 103-117, 1996
39. 39. Bansal GS, Yiangou C, Coope RC, Gomn JJ, Luqmani YA, Coombes RC, Johnston CL: Expression of fibroblast growth factor 1 is lower in breast cancer than in the normal human breast. Br J Cancer 72: 1420-1426, 1995
40. 40. Coope RC, Browne PJ, Yiangou C, Bansal GS, Walters J, Groome N, Shousha S, Johnston CL, Coombes RC, Gomm JJ: The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissues. Br J Cancer 75: 1621-1630, 1997
41. 41. Niedbala MJ, Sartorelli AC: Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. Cancer Res 49: 3302-3309, 1989
42. 42. Kovacs EJ, DiPietro LA: Fibrogenic cytokines and connective tissue production. FASEB J 8: 854-861, 1997
43. 2 production, in human synovial fibroblasts. Proc Nat Acad Sci (Washington) 88: 7180-7184, 1991
44. 44. Idell S, Zweib C, Boggaram J, Holiday D, Johnson AR, Raghu G: Mechanisms of fibrin formation and lysis by human lung fibroblasts: Influence of TGFβ and TNFα. Am Physiol Soc: 487-494, 1992